1. Home
  2. LIDR vs MEIP Comparison

LIDR vs MEIP Comparison

Compare LIDR & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LIDR
  • MEIP
  • Stock Information
  • Founded
  • LIDR 2013
  • MEIP 2000
  • Country
  • LIDR United States
  • MEIP United States
  • Employees
  • LIDR N/A
  • MEIP N/A
  • Industry
  • LIDR Auto Parts:O.E.M.
  • MEIP Biotechnology: Pharmaceutical Preparations
  • Sector
  • LIDR Consumer Discretionary
  • MEIP Health Care
  • Exchange
  • LIDR Nasdaq
  • MEIP Nasdaq
  • Market Cap
  • LIDR 14.8M
  • MEIP 13.3M
  • IPO Year
  • LIDR N/A
  • MEIP 2003
  • Fundamental
  • Price
  • LIDR $0.77
  • MEIP $2.18
  • Analyst Decision
  • LIDR Hold
  • MEIP Hold
  • Analyst Count
  • LIDR 1
  • MEIP 1
  • Target Price
  • LIDR N/A
  • MEIP N/A
  • AVG Volume (30 Days)
  • LIDR 463.9K
  • MEIP 6.4K
  • Earning Date
  • LIDR 08-04-2025
  • MEIP 05-13-2025
  • Dividend Yield
  • LIDR N/A
  • MEIP N/A
  • EPS Growth
  • LIDR N/A
  • MEIP N/A
  • EPS
  • LIDR N/A
  • MEIP N/A
  • Revenue
  • LIDR $246,000.00
  • MEIP N/A
  • Revenue This Year
  • LIDR $2,677.23
  • MEIP N/A
  • Revenue Next Year
  • LIDR $409.09
  • MEIP N/A
  • P/E Ratio
  • LIDR N/A
  • MEIP N/A
  • Revenue Growth
  • LIDR N/A
  • MEIP 33.76
  • 52 Week Low
  • LIDR $0.49
  • MEIP $1.46
  • 52 Week High
  • LIDR $4.30
  • MEIP $4.10
  • Technical
  • Relative Strength Index (RSI)
  • LIDR 58.46
  • MEIP 53.30
  • Support Level
  • LIDR $0.68
  • MEIP $2.05
  • Resistance Level
  • LIDR $0.84
  • MEIP $2.25
  • Average True Range (ATR)
  • LIDR 0.06
  • MEIP 0.11
  • MACD
  • LIDR 0.00
  • MEIP 0.00
  • Stochastic Oscillator
  • LIDR 60.70
  • MEIP 69.91

About LIDR AEye Inc.

AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

Share on Social Networks: